ClinicalTrials.gg
CompletedNCT04282954Updated Jul 13, 2022

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

A Phase 2 interventional study of JP-1366 and JP-1366 placebo in GERD, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2019, registered Feb 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Enrollment
12th of 52
188 · median 54
Started
2019
with 2 others
Phase 2
5 of 71
none open now
Registered
41st of 71
by date

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 12th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 41st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease

03

Conditions studied

  • GERD
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 19 and 75 years old based on the date of written agreement
  • Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA Grade A-D on the upper gastrointestinal endoscopy
  • Those who experienced symptoms of heartburn or acid reflux within the last 7 days

Exclusion criteria

Exclusion Criteria:

  • Those who have undergone gastric acid suppression or gastric, esophageal surgery
  • Those who with liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
  • Clinically significant abnormal laboratory values during screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Group 1

    JP-1366 A mg

    Drug: JP-1366 · Drug: JP-1366 placebo · Drug: Esomeprazole placebo

  • Experimental
    Group 2

    JP-1366 B mg

    Drug: JP-1366 · Drug: JP-1366 placebo · Drug: Esomeprazole placebo

  • Experimental
    Group 3

    JP-1366 C mg

    Drug: JP-1366 · Drug: JP-1366 placebo · Drug: Esomeprazole placebo

  • Active comparator
    Goup 4

    Esomeprazole 40 mg

    Drug: JP-1366 placebo · Drug: Esomeprazole 40mg

Interventions

  • JP-1366, QD

  • DrugJP-1366 placebo

    JP-1366 placebo, QD

  • Esomeprazole 40mg, QD

  • DrugEsomeprazole placebo

    Esomeprazole placebo, QD

06

What researchers measure

Primary outcomes

  1. Accumulated mucosal defect cure rate*(%) at Week 8 following study drug administration (%)

    \* Erosion recovered to normal mucous membrane on upper gastrointestinal endoscopy

    Time frame: 8 weeks

07

Study locations

1 site
  • Severance Hospital and 19 hospitals
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Oct 2020, 11 months.

Of 14 phase 2 interventional studies under Gastroesophageal Reflux, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2020
First posted
Feb 25, 2020
StartActual
Nov 15, 2019
Primary completionActual
Oct 20, 2020
CompletionActual
Dec 11, 2020
Last update
Jul 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04282954
Responsible party
Sponsor
First posted
Feb 25, 2020
Start date
Nov 15, 2019
Primary completion
Oct 20, 2020
Completion
Dec 11, 2020
Last update
Jul 13, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zastaprazan

Start the discussion